Skip to main content
SpringerLink
Log in
Book cover

Principles of Molecular Oncology pp 215–232Cite as

Molecular and Pathological Characterization of Human Tumors

  • Chapter

  • 150 Accesses

Abstract

Histopathologic analysis of tumors has been the linchpin of tissue diagnosis and hence classification. The information provided by histopathologists regarding tumor types and subtypes, tumor grade, and stage forms the core body of information required for clinical management. With increasing use of sophisticated radiology (ultrasound, magnetic resonance imaging [MRI]) and the implementation of screening programs for various diseases (cervical and breast cancer), pathologists are faced with problems of classifying early and borderline lesions and trying to predict their natural history. It is hoped that the new molecular techniques will help provide a molecular classification that is more robust and clinically useful.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cavenee WK, Dryja TP, Phillips RA, et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature. 1983; 305: 779–784.

    Article  PubMed  CAS  Google Scholar 

  2. Kallioniemi A, Kallioniemi OP, Sudar D, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 1992; 258: 818–821.

    Article  PubMed  CAS  Google Scholar 

  3. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995; 270: 467–470.

    Article  PubMed  CAS  Google Scholar 

  4. Chi HS. The role of morphology, cytochemistry and immunohistochemistry in the diagnosis of lymphoproliferative disorders. Int J Hematol. 2002; 76 (Suppl. 2): 9–10.

    Article  PubMed  Google Scholar 

  5. Graadt van Roggen JF, Hogendoorn PC, Fletcher CD. Myxoid tumours of soft tissue. Histopathology. 1999; 35: 291–312.

    Article  PubMed  CAS  Google Scholar 

  6. Andersen J. Determination of estrogen receptors in paraffin-embedded tissue: techniques and the value in breast cancer treatment. Acta Oncol. 1992; 31: 611–627.

    Article  PubMed  CAS  Google Scholar 

  7. Jang KY, Kang MJ, Lee DG, Chung MJ. Utility of thyroid transcription factor-1 and cytokeratin 7 and 20 immunostaining in the identification of origin in malignant effusions. Anal Quant Cytol Histol. 2001; 23: 400–404.

    PubMed  CAS  Google Scholar 

  8. Rubin BP, Skarin AT, Pisick E, Rizk M, Salgia R. Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer. Eur J Cancer Prev. 2001; 10: 77–82.

    Article  PubMed  CAS  Google Scholar 

  9. Srodon M, Westra WH. Immunohistochemical staining for thyroid transcription factor-1: a helpful aid in discerning primary site of tumor origin in patients with brain metastases. Hum Pathol. 2002; 33: 642–645.

    Article  PubMed  CAS  Google Scholar 

  10. Elledge RM, Green S, Ciocca D, et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res. 1998; 4: 7–12.

    PubMed  CAS  Google Scholar 

  11. Pan L, Cesarman E, Knowles DM. Antigen receptor genes: structure, function and genetic analysis of their rearrangement. In: Neoplastic Hematopathology ( Knowles DM, ed.), Lippincott Williams & Wilkins, Philadelphia, PA, 2001; pp. 307–328.

    Google Scholar 

  12. Diss TC, Pan L, Peng H, Wotherspoon AC, Isaacson PG. Sources of DNA for detecting B cell monoclonality using PCR. J Clin Pathol. 1994; 47: 493–496.

    Article  PubMed  CAS  Google Scholar 

  13. Diss TC, Liu HX, Du MQ, Isaacson PG. Improvements to B cell clonality analysis using PCR amplification of immunoglobulin light chain genes. J Clin Pathol: Mol Pathol. 2002; 55: 98–101.

    Article  CAS  Google Scholar 

  14. Diss TC, Pan L. Polymerase chain reaction in the assessment of lymphomas. In: Cancer Surveys, vol. 30 ( Wotherspoon AC eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1997.

    Google Scholar 

  15. Savio A, Franzin G, Wotherspoon AC, et al. Diagnosis and posttreatment follow-up of helicobacter pylori–positive gastric lymphoma of mucosa-associated lymphoid-tissue—histology, polymerase chain-reaction, or both. Blood. 1996; 87: 1255–1260.

    PubMed  CAS  Google Scholar 

  16. Du MQ, Xu CF, Diss TC, et al. Intestinal dissemination of gastric mucosa-associated lymphoid tissue lymphoma. Blood. 1996; 88: 4445–4451.

    PubMed  CAS  Google Scholar 

  17. Du MQ, Peng HZ, Dogan A, et al. Preferential dissemination of B-cell gastric mucosa-associated lymphoid tissue (MALT) lymphoma to the splenic marginal zone. Blood. 1997; 90: 4071–4077.

    PubMed  CAS  Google Scholar 

  18. Du MQ, Diss TC, Dogan A, et al. Clone-specific PCR reveals wide dissemination of gastric MALT lymphoma to the gastric mucosa. J Pathol. 2000; 192: 488–493.

    Article  PubMed  CAS  Google Scholar 

  19. Ashton Key M, Diss TC, Pan L, Du MQ, Isaacson PG. Molecular analysis of T-cell clonality in ulcerative jejunitis and enteropathy-associated T-cell lymphoma. Am J Pathol. 1997; 151: 493–498.

    PubMed  CAS  Google Scholar 

  20. Murray A, Cuevas EC, Jones DB, Wright DH. Study of the immunohistochemistry and T cell clonality of enteropathy-associated T cell lymphoma. Am J Pathol. 1995; 146: 509–519.

    PubMed  CAS  Google Scholar 

  21. Grimwade D, Lo CF. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia. 2002; 16: 1959–1973.

    Article  PubMed  CAS  Google Scholar 

  22. Magnac C, Sutton L, Cazin B, et al. Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL). Hematol Cell Ther. 1999; 41: 13–18.

    Article  PubMed  CAS  Google Scholar 

  23. Billadeau D, Blackstadt M, Greipp P, et al. Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease. Blood. 1991; 78: 3021–3029.

    PubMed  CAS  Google Scholar 

  24. Kuppers R, Klein U, Hansmann ML, Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med. 1999; 341: 1520–1529.

    Article  PubMed  CAS  Google Scholar 

  25. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999; 94: 1848–1854.

    PubMed  CAS  Google Scholar 

  26. Diaz-Cano SJ, Blanes A, Wolfe HJ. PCR techniques for clonality assays. Diagn Mol Pathol. 2001; 10: 24–33.

    Article  PubMed  CAS  Google Scholar 

  27. Levy A. Monoclonality of endocrine tumours: what does it mean? Trends Endocrinol Metab. 2001; 12: 301–307.

    Article  PubMed  CAS  Google Scholar 

  28. Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat. 1998; 52: 65–77.

    Article  PubMed  CAS  Google Scholar 

  29. Leyland-Jones B. Trastuzumab: hopes and realities. Lancet Oncol. 2002; 3: 137–144.

    Article  PubMed  CAS  Google Scholar 

  30. Lichter P, Joos S, Bentz M, Lampel S. Comparative genomic hybridization: uses and limitations. Semin Hematol. 2000; 37: 348–357.

    Article  PubMed  CAS  Google Scholar 

  31. Lakhani SR, Collins N, Stratton MR, Sloane JP. Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol. 1995; 48: 611–615.

    Article  PubMed  CAS  Google Scholar 

  32. Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP. Molecular cytogenetics of primary breast cancer by CGH. Genes Chrom Cancer. 1998; 21: 177–184.

    Article  PubMed  CAS  Google Scholar 

  33. Buerger H, Otterbach F, Simon R, et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol. 1999; 187: 396–402.

    Article  PubMed  CAS  Google Scholar 

  34. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet. 1998; 20: 207–211.

    Article  PubMed  CAS  Google Scholar 

  35. Pollack JR, Perou CM, Alizadeh AA, et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet. 1999; 23: 41–46.

    Article  PubMed  CAS  Google Scholar 

  36. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999; 13: 1901–1928.

    Article  PubMed  Google Scholar 

  37. Du MQ, Isaccson PG. Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol. 2002; 3: 97–104.

    Article  PubMed  CAS  Google Scholar 

  38. Liu H, Ye H, Ruskone-Fourmestraux A, et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology. 2002; 122: 1286–1294.

    Article  PubMed  CAS  Google Scholar 

  39. Knudson AJ. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971; 68: 820–823.

    Article  PubMed  Google Scholar 

  40. Devilee P, Cornelisse CJ. Somatic genetic changes in human breast cancer. Biochim Biophys Acta. 1994; 1198: 113–130.

    PubMed  Google Scholar 

  41. Stratton MR, Collins N, Lakhani SR, Sloane JP. Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol. 1995; 175: 195–201.

    Article  PubMed  CAS  Google Scholar 

  42. Lakhani S, Collins N, Sloane J, Stratton M. Loss of heterozygosity in lobular carcinoma in situ of the breast. J Clin Pathol: Mol Pathol. 1995; 48: M74–M78.

    Article  CAS  Google Scholar 

  43. Barratt PL, Seymour MT, Stenning SP, et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet. 2002; 360: 1381–1391.

    Article  PubMed  CAS  Google Scholar 

  44. Garinis GA, Patrinos GP, Spanakis NE, Menounos PG. DNA hypermethylation: when tumour suppressor genes go silent. Hum Genet. 2002; 111: 115–127.

    Article  PubMed  CAS  Google Scholar 

  45. Bird A. The essentials of DNA methylation. Cell. 1992; 70: 5–8.

    Article  PubMed  CAS  Google Scholar 

  46. Merlo A, Herman JG, Mao L, et al. 5’ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995; 1: 686–692.

    Article  PubMed  CAS  Google Scholar 

  47. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS 1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995; 55: 4525–4530.

    PubMed  CAS  Google Scholar 

  48. Gonzalez-Zulueta M, Bender CM, Yang AS, et al. Methylation of the 5’ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 1995; 55: 4531–4535.

    PubMed  CAS  Google Scholar 

  49. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002; 21: 5427–5440.

    Article  PubMed  CAS  Google Scholar 

  50. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2001; 1: 233–240.

    Article  PubMed  CAS  Google Scholar 

  51. Grann VR, Jacobson JS. Population screening for cancer-related germline gene mutations. Lancet Oncol. 2002; 3: 341–348.

    Article  PubMed  CAS  Google Scholar 

  52. Lipshutz RJ, Fodor SP, Gingeras TR, Lockhart DJ. High density synthetic oligonucleotide arrays. Nat Genet. 1999; 21: 20–24.

    Article  PubMed  CAS  Google Scholar 

  53. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet. 1999; 21: 33–37.

    Article  PubMed  CAS  Google Scholar 

  54. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403: 503–511.

    Article  PubMed  CAS  Google Scholar 

  55. Perou CM, Jeffrey SS, van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA. 1999; 96: 9212–9217.

    Article  PubMed  CAS  Google Scholar 

  56. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747–752.

    Article  PubMed  CAS  Google Scholar 

  57. Jones C, Foschini MP, Chaggar R, et al. Comparative genomic hybridization analysis of myoepithelial carcinoma of the breast. Lab Invest. 2000; 80: 831–836.

    Article  PubMed  CAS  Google Scholar 

  58. Jones C, Nonni AV, Fulford L, et al. CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. B J Cancer. 2001; 85: 422–427.

    Article  CAS  Google Scholar 

  59. Tsuda H, Takarabe T, Hasegawa F, Fukutomi T, Hirohashi S. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol. 2000; 24: 197–202.

    Article  PubMed  CAS  Google Scholar 

  60. van t‘Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415:530–536.

    Google Scholar 

  61. Page MJ, Amess B, Townsend RR, et al. Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci USA. 1999; 96:12, 589–12, 594.

    Google Scholar 

  62. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov. 2002; 1: 683–695.

    Article  PubMed  CAS  Google Scholar 

  63. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002; 359: 572–577.

    Article  PubMed  CAS  Google Scholar 

  64. Wulfkuhle JD, Sgroi DC, Krutzsch H, et al. Proteomics of human breast ductal carcinoma in situ. Cancer Res. 2002; 62: 6740–6749.

    PubMed  CAS  Google Scholar 

  65. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4: 844–847.

    Article  PubMed  CAS  Google Scholar 

  66. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000; 80: 1943–1949.

    Article  PubMed  CAS  Google Scholar 

  67. Khan J, Wei JS, Ringner M, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med. 2001; 7: 673–679.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Chris Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ming-Qing Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sunil R. Lakhani
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Medical Oncology, Hospital General de Granollers, Barcelona, Spain

    Miguel H. Bronchud MD, PhD

  2. Amgen Inc., Thousand Oaks, CA, USA

    MaryAnn Foote PhD

  3. Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands

    Giuseppe Giaccone MD, PhD

  4. Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA

    Olufunmilayo I. Olopade MBBS

  5. Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, UK

    Paul Workman PhD, FMedSci

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Jones, C., Du, MQ., Lakhani, S.R. (2004). Molecular and Pathological Characterization of Human Tumors. In: Bronchud, M.H., Foote, M., Giaccone, G., Olopade, O.I., Workman, P. (eds) Principles of Molecular Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-664-5_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-664-5_6

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-6276-1

  • Online ISBN: 978-1-59259-664-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation